Literature DB >> 25447818

Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.

C Preston Pugh1, Dakota L Pouncey2, Jessica H Hartman1, Robert Nshimiyimana3, Linda P Desrochers3, Thomas E Goodwin3, Gunnar Boysen4, Grover P Miller5.   

Abstract

The widely used anticoagulant Coumadin (R/S-warfarin) undergoes oxidation by cytochromes P450 into hydroxywarfarins that subsequently become conjugated for excretion in urine. Hydroxywarfarins may modulate warfarin metabolism transcriptionally or through direct inhibition of cytochromes P450 and thus, UGT action toward hydroxywarfarin elimination may impact levels of the parent drugs and patient responses. Nevertheless, relatively little is known about conjugation by UDP-glucuronosyltransferases in warfarin metabolism. Herein, we identified probable conjugation sites, kinetic mechanisms and hepatic UGT isoforms involved in microsomal glucuronidation of R- and S-7-hydroxywarfarin. Both compounds underwent glucuronidation at C4 and C7 hydroxyl groups based on elution properties and spectral characteristics. Their formation demonstrated regio- and enantioselectivity by UGTs and resulted in either Michaelis-Menten or substrate inhibition kinetics. Glucuronidation at the C7 hydroxyl group occurred more readily than at the C4 group, and the reaction was overall more efficient for R-7-hydroxywarfarin due to higher affinity and rates of turnover. The use of these mechanisms and parameters to model in vivo clearance demonstrated that contributions of substrate inhibition would lead to underestimation of metabolic clearance than that predicted by Michaelis-Menten kinetics. Lastly, these processes were driven by multiple UGTs indicating redundancy in glucuronidation pathways and ultimately metabolic clearance of R- and S-7-hydroxywarfarin.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  7-Hydroxywarfarin; Glucuronidation; In vitro; Metabolism; UGT (UDP-glucuronosyltransferase); Warfarin

Mesh:

Substances:

Year:  2014        PMID: 25447818      PMCID: PMC4258421          DOI: 10.1016/j.abb.2014.10.006

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  40 in total

1.  Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction.

Authors:  Mike Ufer; Bernd Kammerer; Julia Kirchheiner; Anders Rane; Jan-Olof Svensson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-10-05       Impact factor: 3.205

2.  Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes.

Authors:  A Rulcova; I Prokopova; L Krausova; M Bitman; R Vrzal; Z Dvorak; J Blahos; P Pavek
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

3.  CYP2E1 hydroxylation of aniline involves negative cooperativity.

Authors:  Jessica H Hartman; Katie Knott; Grover P Miller
Journal:  Biochem Pharmacol       Date:  2013-12-15       Impact factor: 5.858

4.  Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6.

Authors:  Soundararajan Krishnaswamy; Su X Duan; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

Review 5.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

6.  Structure of warfarin in solution.

Authors:  E J Valente; E C Lingafelter; W R Porter; W F Trager
Journal:  J Med Chem       Date:  1977-11       Impact factor: 7.446

7.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

Authors:  P J Bosma; J Seppen; B Goldhoorn; C Bakker; R P Oude Elferink; J R Chowdhury; N R Chowdhury; P L Jansen
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

8.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

Review 9.  Modulation of UDP-glucuronosyltransferase activity by protein-protein association.

Authors:  Yuji Ishii; Shuso Takeda; Hideyuki Yamada
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

10.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

Authors:  Verawan Uchaipichat; Peter I Mackenzie; Xiao-Hui Guo; Dione Gardner-Stephen; Aleksandra Galetin; J Brian Houston; John O Miners
Journal:  Drug Metab Dispos       Date:  2004-04       Impact factor: 3.922

View more
  5 in total

1.  Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases.

Authors:  Dustyn A Barnette; Bryce P Johnson; Dakota L Pouncey; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2017-06-23       Impact factor: 3.922

2.  Pharmacokinetic Modeling of Warfarin ІI - Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin.

Authors:  Shen Cheng; Darcy R Flora; Allan E Rettie; Richard C Brundage; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2022-07-07       Impact factor: 3.579

3.  Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.

Authors:  Dakota L Pouncey; Dustyn A Barnette; Riley W Sinnott; Sarah J Phillips; Noah R Flynn; Howard P Hendrickson; S Joshua Swamidass; Grover P Miller
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

4.  USF1 Transcriptionally Regulates UGT1A3 and Promotes Lung Adenocarcinoma Progression by Regulating Neurotrophin Signaling Pathway.

Authors:  Yu Wang; Yun-Xia Zhao; Xiang-Wei Zhang; Yuan-Zhu Jiang; Wei Ma; Lin Zhang; Wei Dong
Journal:  Front Mol Biosci       Date:  2022-01-27

5.  Applicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.

Authors:  Shifra Jammer; Faina Gelman; Ovadia Lev
Journal:  Sci Rep       Date:  2016-03-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.